Clinical and prognostic significance of 3q26.2 and other chromosome 3 abnormalities in CML in the era of tyrosine kinase inhibitors.

@article{Wang2015ClinicalAP,
  title={Clinical and prognostic significance of 3q26.2 and other chromosome 3 abnormalities in CML in the era of tyrosine kinase inhibitors.},
  author={Wei Wang and Jorge E. Cortes and Pei Jen Lin and Michael W. Beaty and D I Ai and Hesham M. Amin and T. J. McDonnell and Chi Young Ok and Hagop M Kantarjian and L Jeffrey Medeiros and Shimin Hu},
  journal={Blood},
  year={2015},
  volume={126 14},
  pages={1699-706}
}
Chromosome 3q26.2 abnormalities in acute myeloid leukemia, including inv(3)/t(3;3) and t(3;21), have been studied and are associated with a poor prognosis. Their prevalence, response to tyrosine kinase inhibitor (TKI) treatment, and prognostic significance in chronic myelogenous leukemia (CML) are largely unknown. In this study, we explored these aspects using a cohort of 2013 patients with CML diagnosed in the era of TKI therapy. Chromosome 3 abnormalities were observed in 116 (5.8%) of 2013… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS
11 Citations
41 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 11 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 41 references

A single oncogenic enhancer rearrangement BLOOD, 1 OCTOBER 2015 x VOLUME 126, NUMBER 14 3Q26.2 AND OTHER CHROMOSOME 3 ABNORMALITIES IN CML

  • S Gröschel, MA Sanders, R Hoogenboezem
  • For personal use only. on September
  • 2016

Similar Papers

Loading similar papers…